Article successfully added.

CyFlow™ CD105 Biotin

CyFlow™ CD105 Biotin
Alternative Name: Endoglin
Antibody: Yes
Antigen: CD105
Application: Flow cytometry
Clonality: monoclonal
Clone: MEM-229
Field of Interest: Immunophenotyping
Format/Fluorochrome: Biotin
Isotype: IgG2a
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human, Pig
Product number: CX641210

For Research Use Only

$188.40 CAD*

Price excludes any applicable taxes plus shipping costs

Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Volume 0.1 mL... more
CyFlow™ CD105 Biotin
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenRecombinant Vaccinia virus containing the human CD105 cDNA
Background InformationCD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFβR-2 as a receptor for TGFβ-1 and TGFβ-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonizes the inhibitory effects of TGFβ-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.
UsageThe reagent is designed for indirect immunofluorescence analysis by Flow Cytometry. Working concentrations should be determined by the investigator.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003 Jul 1; 116(13):2677‑85. < PMID: 12746487 > | Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen‑activated protein kinases in mouse brain microvascular endothelial cells. Stroke. 2003 Oct; 34(10):2483‑8. < PMID: 12947156 > | Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S: CD105 inhibits transforming growth factor‑beta‑Smad3 signalling. Anticancer Res. 2004 May-Jun; 24(3a):1337‑45. < PMID: 15274293 > | Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF‑beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun; 25(3B):1851‑64. < PMID: 16158917 > | Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta‑1 and TGFbeta R‑2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006 Apr; 13(2):82‑9. < PMID: 16733295 > | Plánka L, Necas A, Srnec R, Rauser P, Starý D, Jancár J, Amler E, Filová E, Hlucilová J, Kren L, Gál P: Use of allogenic stem cells for the prevention of bone bridge formation in miniature pigs. Physiol Res. 2009; 58(6):885‑93. < PMID: 19093735 >